Plaintiffs Accept Draft Bill To Settle Hepatitis C Suits (Japan)
This article was originally published in PharmAsia News
Plaintiffs suing the Japanese government and makers of tainted blood products accepted the terms of a draft bill to provide blanket relief to relatives or patients who contracted hepatitis C. The party coalition that rules Japan's Diet drafted the legislation at the urging of the prime minister, and plaintiff acceptance is seen as improving chances for settlement of the suits. Among the draft's provisions is one requiring drug makers of the products to contribute to a $179 billion fund in the Pharmaceuticals and Medical Devices Agency to cover benefits and other payments to patients whose conditions continue to worsen. The proposal is to be presented to the Diet Jan. 7. (Click here for more
You may also be interested in...
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.
Agency explains how it will model vaccine authorization process on its licensing process for matters like inspections and lot release.